{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:59:55Z","timestamp":1792133995995,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2014.00108","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T14:59:16Z","timestamp":1400252356000},"source":"Crossref","is-referenced-by-count":77,"title":["Targeting the PI3K\/mTOR Pathway in Pediatric Hematologic Malignancies"],"prefix":"10.3389","volume":"4","author":[{"given":"Sarah K.","family":"Tasian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"issue":"5","key":"B1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18632\/oncotarget.110","article-title":"Targeting TOR dependence in cancer","volume":"1","author":"Janes","year":"2010","journal-title":"Oncotarget"},{"issue":"5","key":"B3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2165\/11594740-000000000-00000","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Paediatr Drugs"},{"issue":"8","key":"B4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/cas.12189","article-title":"Mechanistic\/mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia","volume":"104","author":"Hirao","year":"2013","journal-title":"Cancer Sci"},{"issue":"3","key":"B5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"B6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3324\/haematol.2009.010785","article-title":"Autocrine IGF-1\/IGF-1R signaling is responsible for constitutive PI3K\/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody","volume":"95","author":"Chapuis","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"B7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"issue":"11","key":"B8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"B9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/leu.2011.46","article-title":"Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway","volume":"25","author":"Martelli","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"B10","first-page":"419","article-title":"mTOR inhibitors in hematologic malignancies","volume":"1","author":"Dancey","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"B11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","article-title":"The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL","volume":"107","author":"Teachey","year":"2006","journal-title":"Blood"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"issue":"1","key":"B14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/1535-7163.MCT-09-0952","article-title":"Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program","volume":"9","author":"Houghton","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"B15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","article-title":"mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"issue":"14","key":"B16","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","article-title":"Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia","volume":"113","author":"Crazzolara","year":"2009","journal-title":"Blood"},{"issue":"11","key":"B17","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","article-title":"Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells","volume":"103","author":"Kharas","year":"2004","journal-title":"Blood"},{"issue":"3","key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","article-title":"Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor","volume":"33","author":"Hirase","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"B19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"21","key":"B20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood.V122.21.2672.2672","article-title":"In vivo efficacy of PI3K pathway signaling inhibition for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"122","author":"Tasian","year":"2013","journal-title":"Blood"},{"issue":"3","key":"B21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children\u00e2\u20ac\u2122s Oncology Group TARGET Project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"issue":"11","key":"B22","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2011-03-341412","article-title":"Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children\u00e2\u20ac\u2122s Oncology Group","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"2","key":"B23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"25","key":"B24","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1073\/pnas.2436348100","article-title":"Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling","volume":"100","author":"Brown","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"B25","doi-asserted-by":"publisher","first-page":"9963","DOI":"10.1158\/0008-5472.CAN-06-4704","article-title":"Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling","volume":"67","author":"Brown","year":"2007","journal-title":"Cancer Res"},{"issue":"17","key":"B26","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"10","key":"B27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat Med"},{"issue":"8","key":"B28","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/0008-5472.CAN-08-4884","article-title":"Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia","volume":"69","author":"Chiarini","year":"2009","journal-title":"Cancer Res"},{"issue":"34","key":"B29","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"B30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"issue":"7380","key":"B31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"20","key":"B32","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","article-title":"Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia","volume":"122","author":"Willems","year":"2013","journal-title":"Blood"},{"issue":"6","key":"B33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.18632\/oncotarget.290","article-title":"Targeting mTOR for the treatment of AML. New agents and new directions","volume":"2","author":"Altman","year":"2011","journal-title":"Oncotarget"},{"issue":"1","key":"B34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","article-title":"Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways","volume":"111","author":"Tamburini","year":"2008","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-1-61779-430-8_15","article-title":"The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia","volume":"821","author":"Janes","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"22","key":"B36","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/1078-0432.CCR-10-0480","article-title":"Target of rapamycin signaling in leukemia and lymphoma","volume":"16","author":"Vu","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"B37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10495-013-0807-9","article-title":"Targeted inhibition of phosphatidyl inositol-3-kinase p110beta, but not p110alpha, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers","volume":"18","author":"Jeong","year":"2013","journal-title":"Apoptosis"},{"issue":"3","key":"B38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T14:33:48Z","timestamp":1597847628000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00108\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3389\/fonc.2014.00108","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}